Selected Financial Data
since 2005
Income Statement
Regeneron Pharmaceuticals Inc., selected items from income statement, long-term trends
US$ in thousands
| 12 months ended: | Revenues | Income (loss) from operations | Net income (loss) |
|---|---|---|---|
| Dec 31, 2024 | 14,202,000) | 3,990,700) | 4,412,600) |
| Dec 31, 2023 | 13,117,200) | 4,047,100) | 3,953,600) |
| Dec 31, 2022 | 12,172,900) | 4,738,900) | 4,338,400) |
| Dec 31, 2021 | 16,071,700) | 8,946,800) | 8,075,300) |
| Dec 31, 2020 | 8,497,100) | 3,576,600) | 3,513,200) |
| Dec 31, 2019 | 7,863,400) | 2,209,800) | 2,115,800) |
| Dec 31, 2018 | 6,710,800) | 2,534,400) | 2,444,400) |
| Dec 31, 2017 | 5,872,227) | 2,079,591) | 1,198,511) |
| Dec 31, 2016 | 4,860,427) | 1,330,741) | 895,522) |
| Dec 31, 2015 | 4,103,728) | 1,251,916) | 636,056) |
| Dec 31, 2014 | 2,819,557) | 838,431) | 348,074) |
| Dec 31, 2013 | 2,104,745) | 760,028) | 424,362) |
| Dec 31, 2012 | 1,378,477) | 457,713) | 750,269) |
| Dec 31, 2011 | 445,824) | (205,159) | (221,760) |
| Dec 31, 2010 | 459,074) | (97,472) | (104,468) |
| Dec 31, 2009 | 379,268) | (74,103) | (67,830) |
| Dec 31, 2008 | 238,457) | (89,830) | (82,710) |
| Dec 31, 2007 | 125,024) | (114,454) | (105,600) |
| Dec 31, 2006 | 63,447) | (107,655) | (102,337) |
| Dec 31, 2005 | 66,193) | (124,421) | (95,446) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Balance Sheet: Assets
Regeneron Pharmaceuticals Inc., selected items from assets, long-term trends
US$ in thousands
| Current assets | Total assets | |
|---|---|---|
| Dec 31, 2024 | 18,660,900) | 37,759,400) |
| Dec 31, 2023 | 19,479,200) | 33,080,200) |
| Dec 31, 2022 | 15,884,100) | 29,214,500) |
| Dec 31, 2021 | 14,014,900) | 25,434,800) |
| Dec 31, 2020 | 9,779,100) | 17,163,300) |
| Dec 31, 2019 | 7,689,100) | 14,805,200) |
| Dec 31, 2018 | 6,447,600) | 11,734,500) |
| Dec 31, 2017 | 4,335,030) | 8,764,286) |
| Dec 31, 2016 | 3,180,188) | 6,973,466) |
| Dec 31, 2015 | 2,915,095) | 5,609,132) |
| Dec 31, 2014 | 2,167,461) | 3,871,827) |
| Dec 31, 2013 | 1,796,934) | 2,951,013) |
| Dec 31, 2012 | 1,206,012) | 2,080,490) |
| Dec 31, 2011 | 652,875) | 1,323,583) |
| Dec 31, 2010 | 357,622) | 1,089,432) |
| Dec 31, 2009 | 425,508) | 741,202) |
| Dec 31, 2008 | 521,442) | 670,038) |
| Dec 31, 2007 | 797,829) | 936,258) |
| Dec 31, 2006 | 469,984) | 585,090) |
| Dec 31, 2005 | 341,392) | 423,501) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Balance Sheet: Liabilities and Stockholders’ Equity
Regeneron Pharmaceuticals Inc., selected items from liabilities and stockholders’ equity, long-term trends
US$ in thousands
| Current liabilities | Total liabilities | Total debt | Stockholders’ equity | |
|---|---|---|---|---|
| Dec 31, 2024 | 3,944,300) | 8,405,800) | 2,704,400) | 29,353,600) |
| Dec 31, 2023 | 3,423,400) | 7,107,100) | 2,702,900) | 25,973,100) |
| Dec 31, 2022 | 3,141,300) | 6,550,500) | 2,701,400) | 22,664,000) |
| Dec 31, 2021 | 3,932,500) | 6,666,000) | 2,699,700) | 18,768,800) |
| Dec 31, 2020 | 2,697,400) | 6,138,000) | 2,695,700) | 11,025,300) |
| Dec 31, 2019 | 2,096,600) | 3,715,500) | 713,900) | 11,089,700) |
| Dec 31, 2018 | 1,442,800) | 2,977,200) | 708,500) | 8,757,300) |
| Dec 31, 2017 | 1,135,483) | 2,620,208) | 703,453) | 6,144,078) |
| Dec 31, 2016 | 1,241,495) | 2,524,221) | 481,126) | 4,449,245) |
| Dec 31, 2015 | 811,162) | 1,954,295) | 375,510) | 3,654,837) |
| Dec 31, 2014 | 654,660) | 1,329,502) | 459,064) | 2,542,325) |
| Dec 31, 2013 | 298,835) | 998,937) | 505,638) | 1,952,076) |
| Dec 31, 2012 | 163,550) | 835,105) | 458,637) | 1,245,385) |
| Dec 31, 2011 | 148,271) | 837,851) | 438,039) | 485,732) |
| Dec 31, 2010 | 109,056) | 561,617) | 162,859) | 527,815) |
| Dec 31, 2009 | 93,575) | 344,440) | 109,022) | 396,762) |
| Dec 31, 2008 | 83,672) | 251,186) | —) | 418,852) |
| Dec 31, 2007 | 283,664) | 475,991) | 200,000) | 460,267) |
| Dec 31, 2006 | 45,014) | 368,466) | 200,000) | 216,624) |
| Dec 31, 2005 | 40,357) | 309,499) | 200,000) | 114,002) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Cash Flow Statement
Regeneron Pharmaceuticals Inc., selected items from cash flow statement, long-term trends
US$ in thousands
| 12 months ended: | Net cash provided by (used in) operating activities | Net cash (used in) provided by investing activities | Net cash provided by (used in) financing activities |
|---|---|---|---|
| Dec 31, 2024 | 4,420,500) | (2,468,100) | (2,200,500) |
| Dec 31, 2023 | 4,594,000) | (3,185,100) | (1,790,100) |
| Dec 31, 2022 | 5,014,900) | (3,784,600) | (1,009,000) |
| Dec 31, 2021 | 7,081,300) | (5,384,700) | (1,005,800) |
| Dec 31, 2020 | 2,618,100) | (70,600) | (1,970,500) |
| Dec 31, 2019 | 2,430,000) | (2,027,800) | (252,100) |
| Dec 31, 2018 | 2,195,100) | (1,463,000) | (77,100) |
| Dec 31, 2017 | 1,307,112) | (1,005,182) | (24,400) |
| Dec 31, 2016 | 1,473,396) | (1,046,904) | (700,391) |
| Dec 31, 2015 | 1,330,780) | (907,601) | (262,796) |
| Dec 31, 2014 | 743,157) | (420,777) | (209,269) |
| Dec 31, 2013 | 583,648) | (355,455) | 77,139) |
| Dec 31, 2012 | (74,615) | (81,073) | (97,646) |
| Dec 31, 2011 | (141,682) | 128,471) | 384,249) |
| Dec 31, 2010 | 99,222) | (437,031) | 243,306) |
| Dec 31, 2009 | (72,230) | 146) | 31,363) |
| Dec 31, 2008 | (89,086) | 30,815) | (192,858) |
| Dec 31, 2007 | 27,372) | (85,723) | 319,400) |
| Dec 31, 2006 | 23,075) | (155,105) | 185,398) |
| Dec 31, 2005 | (30,296) | 115,494) | 4,081) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Per Share Data
Regeneron Pharmaceuticals Inc., selected data per share, long-term trends
US$
| 12 months ended: | Basic earnings per share 1 | Diluted earnings per share 2 | Dividend per share 3 |
|---|---|---|---|
| Dec 31, 2024 | 40.90 | 38.34 | 0.00 |
| Dec 31, 2023 | 37.05 | 34.77 | 0.00 |
| Dec 31, 2022 | 40.51 | 38.22 | 0.00 |
| Dec 31, 2021 | 76.40 | 71.97 | 0.00 |
| Dec 31, 2020 | 32.65 | 30.52 | 0.00 |
| Dec 31, 2019 | 19.38 | 18.46 | 0.00 |
| Dec 31, 2018 | 22.65 | 21.29 | 0.00 |
| Dec 31, 2017 | 11.27 | 10.34 | 0.00 |
| Dec 31, 2016 | 8.55 | 7.70 | 0.00 |
| Dec 31, 2015 | 6.17 | 5.52 | 0.00 |
| Dec 31, 2014 | 3.46 | 3.07 | 0.00 |
| Dec 31, 2013 | 4.33 | 3.81 | 0.00 |
| Dec 31, 2012 | 7.92 | 6.75 | 0.00 |
| Dec 31, 2011 | -2.45 | -2.45 | 0.00 |
| Dec 31, 2010 | -1.26 | -1.26 | 0.00 |
| Dec 31, 2009 | -0.85 | -0.85 | 0.00 |
| Dec 31, 2008 | -1.05 | -1.05 | 0.00 |
| Dec 31, 2007 | -1.59 | -1.59 | 0.00 |
| Dec 31, 2006 | -1.77 | -1.77 | 0.00 |
| Dec 31, 2005 | -1.71 | -1.71 | 0.00 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1, 2, 3 Data adjusted for splits and stock dividends.